{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:49:24Z","timestamp":1771480164812,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Open Research Project of Key Laboratories of Jiangsu Province Universities","award":["XZSYSKF2023015"],"award-info":[{"award-number":["XZSYSKF2023015"]}]},{"name":"Open Research Project of Key Laboratories of Jiangsu Province Universities","award":["XZSYSKF2023015"],"award-info":[{"award-number":["XZSYSKF2023015"]}]},{"name":"Open Research Project of Key Laboratories of Jiangsu Province Universities","award":["XZSYSKF2023015"],"award-info":[{"award-number":["XZSYSKF2023015"]}]},{"name":"China Health Promotion Foundation \"Love Lungs\" Tumor Treatment Clinical Research Innovation Public Welfare Project","award":["AF-013"],"award-info":[{"award-number":["AF-013"]}]},{"name":"Jiangsu Province's 14th Five-Year Plan Key Medical Discipline \"Tumor Therapy\"","award":["ZDXK202237"],"award-info":[{"award-number":["ZDXK202237"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors targeting PD-1 show limited efficacy in non-small cell lung cancer (NSCLC) due to primary resistance. KIF20A, a cell cycle regulator implicated in chemotherapy resistance, may influence tumor immunity, but its role in anti-PD-1 resistance remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed comprehensive bioinformatics analyses to identify KIF20A as a resistance-associated hub gene. Clinical validation was performed in 106 NSCLC patients receiving anti-PD-1 therapy. KIF20A protein expression was assessed by immunohistochemistry (IHC), and tumor microenvironment (TME) profiling was performed using multiplex immunofluorescence (mIHC). Statistical analyses included chi-square tests, Kaplan-Meier survival, Cox regression, and Spearman correlation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      KIF20A was significantly upregulated in NSCLC versus adjacent tissues (63.2% vs. 13.2%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and associated with lymph node metastasis, poor differentiation, and advanced stage (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). High KIF20A expression correlated with primary resistance to PD-1 blockade (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.019) and shorter post-immunotherapy overall survival (HR\u2009=\u20093.40,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.016). Crucially, KIF20A-high tumors exhibited reduced PD-L1\u207a tumor cell density (375.4\/mm\u00b2 vs. 864.8\/mm\u00b2 in KIF20A-low tumors,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0002), with an inverse correlation (\n                      <jats:italic>r<\/jats:italic>\n                      =-0.249,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01). Patients with combined KIF20A-high\/PD-L1-low expression had the worst prognosis (HR\u2009=\u20096.61,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.030).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>KIF20A drives primary anti-PD-1 resistance in NSCLC through PD-L1 suppression and independently predicts poor survival. The KIF20A\/PD-L1 signature stratifies patient risk, positioning KIF20A as both a prognostic biomarker and a therapeutic target to overcome immunotherapy resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15221-6","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:12:08Z","timestamp":1763644328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Tianyu","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaonan","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"3","key":"15221_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2022;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Cancer J Clin"},{"issue":"6","key":"15221_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"15221_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in Lung-Cancer treatment on population Mortality, N. Engl. J Med. 2020;383(7):640\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1916623.","journal-title":"J Med"},{"issue":"5 Suppl","key":"15221_CR4","doi-asserted-by":"publisher","first-page":"eS341","DOI":"10.1378\/chest.12-2361","volume":"143","author":"MA Socinski","year":"2013","unstructured":"Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):eS341-68. https:\/\/doi.org\/10.1378\/chest.12-2361.","journal-title":"Chest"},{"issue":"7689","key":"15221_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354. https:\/\/doi.org\/10.1038\/nature25183.","journal-title":"Nature"},{"issue":"1","key":"15221_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","volume":"17","author":"N Boku","year":"2014","unstructured":"Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17(1):1\u201312. https:\/\/doi.org\/10.1007\/s10120-013-0252-z.","journal-title":"Gastric Cancer"},{"issue":"1","key":"15221_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40. https:\/\/doi.org\/10.1186\/s12943-023-01740-y.","journal-title":"Mol Cancer"},{"issue":"1","key":"15221_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28. https:\/\/doi.org\/10.1186\/s12943-021-01489-2.","journal-title":"Mol Cancer"},{"issue":"19","key":"15221_CR9","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-Positive Non-Small-Cell lung Cancer, N. Engl. J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"J Med"},{"issue":"25","key":"15221_CR10","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-Line nivolumab in stage IV or recurrent Non-Small-Cell lung Cancer, N. Engl. J Med. 2017;376(25):2415\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613493.","journal-title":"J Med"},{"issue":"17","key":"15221_CR11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/jco.2017.77.0412","volume":"36","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-Year Follow-Up of nivolumab in previously treated advanced Non-Small-Cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675\u201384. https:\/\/doi.org\/10.1200\/jco.2017.77.0412.","journal-title":"J Clin Oncol"},{"issue":"6","key":"15221_CR12","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-Specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259-e127111. https:\/\/doi.org\/10.1016\/j.cell.2017.10.001.","journal-title":"Cell"},{"key":"15221_CR13","doi-asserted-by":"publisher","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-Mutant lung adenocarcinoma. Cancer Discov. 2018;7822\u201335. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0099.","DOI":"10.1158\/2159-8290.Cd-18-0099"},{"issue":"3","key":"15221_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.gendis.2019.06.006","volume":"6","author":"H Shen","year":"2019","unstructured":"Shen H, Yang ES, Conry M, Fiveash J, Contreras C, Bonner JA, et al. Predictive biomarkers for immune checkpoint Blockade and opportunities for combination therapies. Genes Dis. 2019;6(3):232\u201346. https:\/\/doi.org\/10.1016\/j.gendis.2019.06.006.","journal-title":"Genes Dis"},{"issue":"6","key":"15221_CR15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, V\u00e9tizou M, Daill\u00e8re R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to Immune-Checkpoint Blockade in cancer: Tumor-Intrinsic and -Extrinsic factors. Immunity. 2016;44(6):1255\u201369. https:\/\/doi.org\/10.1016\/j.immuni.2016.06.001.","journal-title":"Immunity"},{"issue":"4","key":"15221_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"issue":"7693","key":"15221_CR17","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 Blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"issue":"1","key":"15221_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41421-023-00529-z","volume":"9","author":"GQ Zhu","year":"2023","unstructured":"Zhu GQ, Tang Z, Huang R, Qu WF, Fang Y, Yang R, et al. CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discovery. 2023;9(1):25. https:\/\/doi.org\/10.1038\/s41421-023-00529-z.","journal-title":"Cell Discovery"},{"issue":"7668","key":"15221_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 Inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u20135. https:\/\/doi.org\/10.1038\/nature23465.","journal-title":"Nature"},{"issue":"23","key":"15221_CR20","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1038\/s41388-019-0733-6","volume":"38","author":"TBM Permata","year":"2019","unstructured":"Permata TBM, Hagiwara Y, Sato H, Yasuhara T, Oike T, Gondhowiardjo S. Base excision repair regulates PD-L1 expression in cancer cells. Oncogene. 2019;38(23):4452\u201366. https:\/\/doi.org\/10.1038\/s41388-019-0733-6.","journal-title":"Oncogene"},{"issue":"1","key":"15221_CR21","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8(1):1751. https:\/\/doi.org\/10.1038\/s41467-017-01883-9.","journal-title":"Nat Commun"},{"issue":"3","key":"15221_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.Cd-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of neoantigen landscape during immune checkpoint Blockade in Non-Small cell lung cancer. Cancer Discov. 2017;7(3):264\u201376. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0828.","journal-title":"Cancer Discov"},{"key":"15221_CR23","doi-asserted-by":"publisher","unstructured":"Ghosh S, O\u2019Hara MP, Sinha P, Mazumdar T, Yapindi L, Sastry JK, et al. Targeted Inhibition of Aurora kinase A promotes immune checkpoint Inhibition efficacy in human papillomavirus-driven cancers. J Immunother Cancer. 2025;13(1). https:\/\/doi.org\/10.1136\/jitc-2024-009316.","DOI":"10.1136\/jitc-2024-009316"},{"key":"15221_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejcb.2018.12.002","volume":"98","author":"WD Wu","year":"2019","unstructured":"Wu WD, Yu KW, Zhong N, Xiao Y, She ZY. Roles and mechanisms of Kinesin-6 KIF20A in spindle organization during cell division. Eur J Cell Biol. 2019;98:2\u20134. https:\/\/doi.org\/10.1016\/j.ejcb.2018.12.002.","journal-title":"Eur J Cell Biol"},{"issue":"20","key":"15221_CR25","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41388-022-02307-9","volume":"41","author":"VA Copello","year":"2022","unstructured":"Copello VA, Burnstein KL. The Kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor. Oncogene. 2022;41(20):2824\u201332. https:\/\/doi.org\/10.1038\/s41388-022-02307-9.","journal-title":"Oncogene"},{"issue":"8","key":"15221_CR26","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/onc.2015.152","volume":"35","author":"P Khongkow","year":"2016","unstructured":"Khongkow P, Gomes AR, Gong C, Man EP, Tsang JW, Zhao F, et al. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer Paclitaxel resistance. Oncogene. 2016;35(8):990\u20131002. https:\/\/doi.org\/10.1038\/onc.2015.152.","journal-title":"Oncogene"},{"issue":"10","key":"15221_CR27","doi-asserted-by":"publisher","first-page":"13515","DOI":"10.18632\/aging.202774","volume":"13","author":"C Yang","year":"2021","unstructured":"Yang C, Zhang Y, Lin S, Liu Y, Li W. Suppressing the KIF20A\/NUAK1\/Nrf2\/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin. Aging (Albany N Y). 2021;13(10):13515\u201334. https:\/\/doi.org\/10.18632\/aging.202774.","journal-title":"Aging (Albany N Y)"},{"issue":"24","key":"15221_CR28","doi-asserted-by":"publisher","first-page":"11905","DOI":"10.18632\/aging.102505","volume":"11","author":"M Xiong","year":"2019","unstructured":"Xiong M, Zhuang K, Luo Y, Lai Q, Luo X, Fang Y, et al. KIF20A promotes cellular malignant behavior and enhances resistance to chemotherapy in colorectal cancer through regulation of the JAK\/STAT3 signaling pathway. Aging (Albany N Y). 2019;11(24):11905\u201321. https:\/\/doi.org\/10.18632\/aging.102505.","journal-title":"Aging (Albany N Y)"},{"key":"15221_CR29","doi-asserted-by":"publisher","first-page":"621430","DOI":"10.3389\/fonc.2021.621430","volume":"11","author":"J Jiang","year":"2021","unstructured":"Jiang J, Liu C, Xu G, Liang T, Yu C, Liao S, et al. Identification of hub genes associated with melanoma development by comprehensive bioinformatics analysis. Front Oncol. 2021;11:621430. https:\/\/doi.org\/10.3389\/fonc.2021.621430.","journal-title":"Front Oncol"},{"issue":"1","key":"15221_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3892\/ijo.2020.5060","volume":"57","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Takano A, Thang PM, Tsevegjav B, Zhu M, Yokose T, et al. Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer. Int J Oncol. 2020;57(1):277\u201388. https:\/\/doi.org\/10.3892\/ijo.2020.5060.","journal-title":"Int J Oncol"},{"issue":"16","key":"15221_CR31","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1158\/1078-0432.Ccr-13-0197","volume":"19","author":"Y Tomita","year":"2013","unstructured":"Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, et al. Identification of promiscuous KIF20A long peptides bearing both CD4\u2009+\u2009and CD8\u2009+\u2009T-cell epitopes: KIF20A-specific CD4\u2009+\u2009T-cell immunity in patients with malignant tumor. Clin Cancer Res. 2013;19(16):4508\u201320. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0197.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15221_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-016-2360-1","volume":"132","author":"K Saito","year":"2017","unstructured":"Saito K, Ohta S, Kawakami Y, Yoshida K, Toda M. Functional analysis of KIF20A, a potential immunotherapeutic target for glioma. J Neurooncol. 2017;132(1):63\u201374. https:\/\/doi.org\/10.1007\/s11060-016-2360-1.","journal-title":"J Neurooncol"},{"key":"15221_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/1479-5876-11-291","volume":"11","author":"S Asahara","year":"2013","unstructured":"Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I\/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med. 2013;11:291. https:\/\/doi.org\/10.1186\/1479-5876-11-291.","journal-title":"J Transl Med"},{"key":"15221_CR34","doi-asserted-by":"publisher","unstructured":"Ding ZC, Zhou G. Cytotoxic chemotherapy and CD4\u2009+\u2009effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol. 2012;(2012):890178. https:\/\/doi.org\/10.1155\/2012\/890178.","DOI":"10.1155\/2012\/890178"},{"issue":"2","key":"15221_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.bjc.6606052","volume":"104","author":"K Imai","year":"2011","unstructured":"Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, et al. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer. 2011;104(2):300\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6606052.","journal-title":"Br J Cancer"},{"issue":"11","key":"15221_CR36","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, et al. PARP Inhibition elicits STING-Dependent antitumor immunity in Brca1-Deficient ovarian cancer. Cell Rep. 2018;25(11):2972-e29805. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.054.","journal-title":"Cell Rep"},{"issue":"7","key":"15221_CR37","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W. Smyth, Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"key":"15221_CR38","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48W1","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48W1:W509-14. https:\/\/doi.org\/10.1093\/nar\/gkaa407.","journal-title":"Nucleic Acids Res"},{"key":"15221_CR39","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47W1","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47W1:W556\u201360. https:\/\/doi.org\/10.1093\/nar\/gkz430.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"15221_CR40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bph.16257","volume":"181","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br J Pharmacol. 2024;181(3):362\u201374. https:\/\/doi.org\/10.1111\/bph.16257.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"15221_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"FC Detterbeck","year":"2017","unstructured":"Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193\u2013203. https:\/\/doi.org\/10.1016\/j.chest.2016.10.010.","journal-title":"Chest"},{"issue":"2","key":"15221_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"15221_CR43","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.2147\/ott.S115974","volume":"9","author":"J Duan","year":"2016","unstructured":"Duan J, Huang W, Shi H. Positive expression of KIF20A indicates poor prognosis of glioma patients. Onco Targets Ther. 2016;9:6741\u20139. https:\/\/doi.org\/10.2147\/ott.S115974.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"15221_CR44","doi-asserted-by":"publisher","first-page":"e0169280","DOI":"10.1371\/journal.pone.0169280","volume":"12","author":"SL Liu","year":"2017","unstructured":"Liu SL, Lin HX, Qiu F, Zhang WJ, Niu CH, Wen W, et al. Overexpression of Kinesin family member 20A correlates with disease progression and poor prognosis in human nasopharyngeal cancer: A retrospective analysis of 105 patients. PLoS ONE. 2017;12(1):e0169280. https:\/\/doi.org\/10.1371\/journal.pone.0169280.","journal-title":"PLoS ONE"},{"key":"15221_CR45","doi-asserted-by":"publisher","first-page":"993820","DOI":"10.3389\/fbioe.2022.993820","volume":"10","author":"D Sun","year":"2022","unstructured":"Sun D, Zhang H, Zhang C, Wang L. An evaluation of KIF20A as a prognostic factor and therapeutic target for lung adenocarcinoma using integrated bioinformatics analysis. Front Bioeng Biotechnol. 2022;10:993820. https:\/\/doi.org\/10.3389\/fbioe.2022.993820.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"15221_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jss.2015.03.070","volume":"197","author":"D Stangel","year":"2015","unstructured":"Stangel D, Erkan M, Buchholz M, Gress T, Michalski C, Raulefs S, et al. Kif20a Inhibition reduces migration and invasion of pancreatic cancer cells. J Surg Res. 2015;197(1):91\u2013100. https:\/\/doi.org\/10.1016\/j.jss.2015.03.070.","journal-title":"J Surg Res"},{"key":"15221_CR47","doi-asserted-by":"publisher","first-page":"100907","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, Shi ZD, Wei LY, Dong Y, Ma YY, Wang W, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 Blockade. Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother. 2023;66:100907. https:\/\/doi.org\/10.1016\/j.drup.2022.100907.","journal-title":"Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother"},{"key":"15221_CR48","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"15221_CR49","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","volume":"8","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, et al. Association of high tumor mutation burden in Non-Small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 Blockade across PD-L1 expression levels. JAMA Oncol. 2022;8(8):1160\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1981.","journal-title":"JAMA Oncol"},{"issue":"6230","key":"15221_CR50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science (New York, N.Y.). 2015;348(6230):74\u201380. https:\/\/doi.org\/10.1126\/science.aaa6204.","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"15221_CR51","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","volume":"11","author":"M Liu","year":"2018","unstructured":"Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang S, et al. Targeting the IDO1 pathway in cancer: from bench to bedside. J Hematol Oncol. 2018;11(1):100. https:\/\/doi.org\/10.1186\/s13045-018-0644-y.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"15221_CR52","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu M, Butti R, Panda VK, Malhotra D, Das S, Mitra T, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol Cancer. 2024;23(1):92. https:\/\/doi.org\/10.1186\/s12943-024-01990-4.","journal-title":"Mol Cancer"},{"key":"15221_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to Anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374. https:\/\/doi.org\/10.1146\/annurev-immunol-070621-030155","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"15221_CR54","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","volume":"11","author":"M Jiang","year":"2021","unstructured":"Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sinica B. 2021;11(10):2983\u201394. https:\/\/doi.org\/10.1016\/j.apsb.2021.01.003.","journal-title":"Acta Pharm Sinica B"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15221-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:12:09Z","timestamp":1763644329000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15221-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15221"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15221-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical standards of the Declaration of Helsinki and approved by the Biomedical Research Ethics Committee of Xuzhou Central Hospital (Approval No: XZXY-LK-20240129-0024). Informed consent to participate was waived by the Ethics Committee due to the retrospective nature of the study and the use of anonymized archival formalin-fixed paraffin-embedded specimens.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1794"}}